Global Citizens’ Human Rights Coalition join 100 Organizations to Rally for the Dissolution of the CCK

Global Citizens Human Rights Coalition join 100 Organizations to Rally for the Dissolution of the CCK
Washington, D.C., January 30th, 2019 –(PRWirePro.com)– On Jan. 27, over 30,000 people from civil society organizations and religious groups came together at Gwanghwamun Square in a rally coordinated by the Global Citizens’ Human Rights Coalition.

The coalition formed against the CCK is comprised of 100 organizations in South Korea. Several of the larger organizations include the International Women’s Peace Human Rights Commission, the Christian Association for Anti-Corruption National Movement and the World Buddhist Summit.

In a press conference following the rally, International Women’s Peace Human Rights Commission’s Chairperson Seoyeon Lee stated, “President Moon and his government should heed the voices of law-abiding citizens and protect their human rights. We request the rapid enactment of a law to ban and punish coercive conversion programs and to end coercive conversion which suppresses the right to freedom of religion.”


PR Contact:
Alex Woodard

Company
AVCCP

Sutro Achieves $10 Million Milestone Payment from Celgene

San Francisco, CA, December 19, 2018 –(PRWirePro.com)– Sutro Biopharma, Inc. (NASDAQ:STRO), today announced that the company earned $10 million in a milestone payment from Celgene triggered by the successful development of a dry powder XtractCFTM formulation, using spray drying technology, which is well established in the pharmaceutical industry. Dried XtractCFTM is a significant advancement, facilitating the commercial-scale manufacturing of protein therapeutics, using Sutro’s proprietary cell-free XpressCFTM technology for its fully owned and partnered programs.

VIEW FULL PRESS RELEASE

Neuronetics Announces Preliminary Fourth Quarter and Full Year Revenue

Malvern, PA, January 7, 2019 –(PRWirePro.com)– Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced certain unaudited preliminary fourth quarter and full year 2018 revenue. Preliminary fourth quarter 2018 revenue of approximately $15.6 million, an increase of approximately 29% over the fourth quarter of 2017. Preliminary fourth quarter 2018 U.S. treatment session revenue of approximately $9.9 million, an increase of approximately 23% over the fourth quarter of 2017.

VIEW FULL PRESS RELEASE